Breckenridge Pharmaceutical, Inc. has issued a nationwide voluntary recall of one lot of Propranolol Hydrochloride Extended-Release Capsules, 60 mg, after discovering a potential risk of metal contamination that could cause injuries to patients who take the medication.

The affected capsules were distributed to wholesalers and pharmacies across the country between Oct. 26 and Nov. 4, 2026. The recall applies specifically to 100-count bottles bearing lot number PK25110035, National Drug Code (NDC) 51991-817-01, and an expiration date of May 2029. The white capsules are manufactured by Adare Pharma.

The company warned that metal fragments could cause lacerations to soft tissue in the mouth, esophagus, stomach or intestines. The affected lot shared intermediate manufacturing material suspected of being responsible for metal contamination discovered in a separate lot that was never released for sale.

Breckenridge said it has not received reports of adverse health events connected to the recalled medication. Nevertheless, the company instructed consumers to immediately stop taking capsules from the affected lot and contact their physician or healthcare provider for medical advice and replacement instructions.

Patients who have the recalled medication should return any unused portions to the pharmacy where they obtained the prescription. Anyone who experiences a medical problem potentially associated with the capsules should contact a healthcare provider and report the incident through the Food and Drug Administration's MedWatch Adverse Event Reporting program.

The company also directed wholesalers, pharmacies and other retailers to inspect their inventories, quarantine any bottles from the affected lot and stop distributing or dispensing them.

Propranolol is a beta-blocker commonly prescribed to treat high blood pressure by reducing heart rate and lowering the workload on the heart. Extended-release versions may also be prescribed for conditions including chest pain, migraines and tremors.

The recall comes amid other recent problems involving blood pressure medications. Earlier in November, a separate nationwide recall targeted tablets containing olmesartan medoxomil, amlodipine and hydrochlorothiazide after they failed dissolution testing. Thousands of bottles of chlorthalidone tablets were also recalled earlier this fall over similar concerns involving their ability to dissolve properly.